Advertisement

Topics

Anokion Elects Michael Clayman, M.D., as Chairman of its Board of Directors

08:00 EDT 14 Jun 2018 | Businesswire

This article has expired, however you can still download the PDF.
Preview:
Anokion (“Anokion” or the “Company”), a privately held biopharmaceutical company developing novel tolerance-inducing therapeutics for autoimmune diseases, today announced that Michael D. Clayman, M.D., president, chief e...

Other Sources for this Article

Anokion
Deb Geraghty, Ph.D., +1-857-320-6635
deb.geraghty@anokion.com

NEXT ARTICLE

More From BioPortfolio on "Anokion Elects Michael Clayman, M.D., as Chairman of its Board of Directors"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Autoimmune Disorders
Autoimmune disorders are conditions that occurs when the immune system mistakenly attacks and destroys healthy body tissue. There are more than 80 different types of autoimmune disorders. Normally the immune system's white blood cells help protect ...

Biopharmaceuticals
Biopharmaceuticals are medical drugs produced using biotechnology. They include proteins (including antibodies), nucleic acids (DNA, RNA or antisense oligonucleotides) and living microorganisms like virus and bacteria where the virulance of viruses and b...